Patent review of cannabinoid receptor type 2 (CB

Agonist G protein-coupled receptor antagonist cannabinoid receptor type 2 fibrosis inflammation

Journal

Expert opinion on therapeutic patents
ISSN: 1744-7674
Titre abrégé: Expert Opin Ther Pat
Pays: England
ID NLM: 9516419

Informations de publication

Date de publication:
17 Jun 2024
Historique:
medline: 18 6 2024
pubmed: 18 6 2024
entrez: 17 6 2024
Statut: aheadofprint

Résumé

Cannabinoid receptor type 2 (CB This review is an account of patents from 2016 up to 2023 which describes novel CB The patents cover a vast, structurally diverse chemical space. The focus of CB

Identifiants

DOI: 10.1080/13543776.2024.2368745 PMID: 38886185
pubmed: 38886185
doi: 10.1080/13543776.2024.2368745
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Miroslav Kosar (M)

Laboratorium für Organische Chemie, Eidgenössische Technische Hochschule Zürich, Zürich, Switzerland.

Leonard Mach (L)

Medicinal Chemistry, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP)Berlin, Berlin, Germany.

Erick M Carreira (EM)

Laboratorium für Organische Chemie, Eidgenössische Technische Hochschule Zürich, Zürich, Switzerland.

Marc Nazaré (M)

Medicinal Chemistry, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP)Berlin, Berlin, Germany.

Pal Pacher (P)

National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, USA.

Uwe Grether (U)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Classifications MeSH